Phaseline

Companies › Iterion Therapeutics

Iterion Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 7 registered trials: 7 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tegavivint
Wnt signaling pathway inhibitor
–Phase 1Advanced Hepatocellular Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Leukemia; Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05797805TegavivintPhase 1Advanced Hepatocellular CarcinomaOncologyMay 2026
NCT04780568TegavivintPhase 1Metastatic Lung Non-Small Cell CarcinomaOncologyDec 2026
NCT04874480TegavivintPhase 1Recurrent LeukemiaOncologyFeb 2027
NCT05755087TegavivintPhase 1Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell TypeOncologyMar 2028
NCT07144254TegavivintPhase 1Osteosarcoma RecurrentOncologyMay 2028
NCT04851119TegavivintPhase 1Colorectal CarcinomaOncologyJun 2028
NCT07463599TegavivintPhase 1Metastatic Colorectal Carcinoma (mCRC)OncologyJan 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.